The authors reply

New England Journal of Medicine

Volumn 358, Issue 23, 2008, Pages 2515-2516

  Phillips, Elizabeth ^a   Nolan, David ^a   Mallal, Simon ^a  

^a MURDOCH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; HLA B ANTIGEN; HLA B5701 ANTIGEN; PLACEBO;

ALLELE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG HYPERSENSITIVITY; ETHNIC DIFFERENCE; FALSE POSITIVE RESULT; GENETIC SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PATCH TEST; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL;

EID: 44849117152     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. Phillips EJ, Mallal SA. Pharmacogenetics and the potential for the individualization of antiretroviral therapy. Curr Opin Infect Dis 2008;21:16-24.
2. Saag M, Balu R, Phillips E, et al. High sensitivity of human leukocyte antigen-B*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis 2008;46:1111-8.
3. Phillips EJ. Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet? Clin Infect Dis 2006;43:103-5.